

RANDOMISED, OPEN-LABEL STUDY TO EVALUATE 2 INTRAVITREAL AFLIBERCEPT TREAT-AND-EXTEND DOSING REGIMENS IN WET AGE-RELATED MACULAR DEGENERATION: 52-WEEK OUTCOMES FROM ALTAIR

Purpose: To evaluate 2 intravitreal aflibercept (IVT- AFL) treat-and-extend (T&E) dosing regimens in Japanese patients with wet age-related macular degeneration (wAMD).

Methods: ALTAIR (NCT02305238) was a 96-week, randomised, open-label, Phase 4 study conducted at 40 sites across Japan. Patients received 3 monthly doses of IVT-AFL before randomisation (1:1) at Week 16 to IVT-AFL with a 2-week (IVT-AFL-2W) or 4-week (IVT-AFL-4W) adjustment. Primary end- point was mean change in best-corrected visual acuity (BCVA; Early Treatment Diabetic Retinopathy Study [ETDRS] letters) from baseline to Week 52. Other endpoints included the proportion of patients losing